-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2023-509292-17-00
4
2024-11-08
primary high-risk lobular breast cancer
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2023-506617-21-00
5
2024-08-29
Major depressive disorder
-
2023-507925-41-00
5
2024-08-14
Scabies
-
2022-502559-69-01
4
2024-07-04
advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
-
2023-508271-36-00
6
2024-04-30
incomplete meniscal loss
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2024-516634-35-00
6
2024-02-01
Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
-
2022-500453-16-00
4
2023-10-30
Multiple Myeloma
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2022-501808-96-00
4
2023-05-15
Mantle Cell Lymphoma
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-505438-85-00
5
2022-01-12
Acute myocardial infarction (AMI)
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2025-521912-21-00
4
2026-01-26
Cardiovascular risk reduction in participants with elevated Lp(a)